Results 31 to 40 of about 391 (114)

Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study

open access: yesLife, 2021
Psoriasis is a chronic, inflammatory skin disease present in about 3% of the world’s population. The clinical symptoms manifest diversely, therefore one can distinguish several subtypes of psoriasis.
Kamila Jaworecka   +12 more
doaj   +1 more source

Von Zumbusch’s pustular psoriasis associated with oral terbinafine

open access: yesJournal of Dermatology and Dermatologic Surgery, 2017
Adverse skin reactions have been reported in 2.7% of patients receiving oral terbinafine. Less common but life-threatening reactions include acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis ...
Naoufal Hjira   +5 more
doaj   +1 more source

Dermatologic Best Practices for Manicures and Nail Care: A Systematic Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Manicure and pedicure procedures are widely viewed as benign cosmetic practices, yet emerging evidence links them to various dermatologic complications, including dermatitis, infection, photodamage and, in rare cases, cutaneous malignancy.
Nivetha Aravind   +2 more
wiley   +1 more source

Economic Burden of Generalized Pustular Psoriasis: A Population-based Register Study in Finland

open access: yesActa Dermato-Venereologica
Generalized pustular psoriasis is an inflammatory disease characterized by potentially life-threatening flares. This study assessed the economic burden of generalized pustular psoriasis in Finland by comparing healthcare resource utilization and both ...
Xavier Teitsma   +9 more
doaj   +1 more source

IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis

open access: yesBMC Nephrology, 2020
Background IgA nephropathy is the most common glomerulonephritis. Secondary IgA nephropathy complicated with systemic diseases, including psoriasis, is also often reported.
Yuka Segawa   +9 more
doaj   +1 more source

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO‐1, PSO‐4, and Long‐Term Extension Trials

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo   +12 more
wiley   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada   +9 more
wiley   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo   +6 more
wiley   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy